NCT04329949 - Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

August 23, 2021

Study Completion Date

March 25, 2022

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

Relacorilant, 100 mg and 25 mg

Relacorilant is supplied as capsules for oral dosing.

DRUG

Nab-paclitaxel

Nab-paclitaxel is administered as IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle.

Trial Locations (18)

10016

Site #044, New York

Site #222, New York

14263

Site #182, Buffalo

15232

Site #172, Pittsburgh

21231

Site #065, Baltimore

30322

Site #009, Atlanta

37232

Site #176, Nashville

37920

Site #175, Knoxville

43210

Site #077, Columbus

43614

Site #186, Toledo

46526

Site #184, Goshen

48201

Site #058, Detroit

68114

Site #185, Omaha

80045

Site #032, Aurora

85258

Site #038, Scottsdale

90095

Site #076, Los Angeles

91010

Site #171, Duarte

98195

Site #173, Seattle